BN 50730

platelet activating factor antagonist; structure given in first source

Also Known As:

6-(2-chlorophenyl)-9-((4-methoxyphenyl)thiocarbamoyl)-1-methyl-7,8,9,10-tetrahydro-4H-pyrido(4',3'-4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine; BN-50730; BN50730; LAU 8080; LAU-8080; LAU8080

Networked: 10 relevant articles (3 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiophenes: 257
    - Thienopyridines: 211
      - BN 50730: 10
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Thiophenes: 257
    - Thienopyridines: 211
      - BN 50730: 10
  - Pyridines: 88
    - Thienopyridines: 211
      - BN 50730: 10
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Thienopyridines: 211
      - BN 50730: 10

Experts

1.	Hunt, J D: 1 article (11/2001)
2.	Robert, E G: 1 article (11/2001)
3.	Barks, J D: 1 article (06/2001)
4.	Eun, B L: 1 article (06/2001)
5.	Liu, X H: 1 article (06/2001)

Related Diseases

1.	Neoplasms (Cancer) 11/01/2001 - "In particular BN-50730, a PAF antagonist shows promise in preliminary anti-tumor therapy in vitro and in vivo in athymic nude mice by specifically inhibiting angiogenesis." 04/01/1993 - "Platelet-activating factor antagonists (BN 52021 and BN 50730) inhibit tumor necrosis factor-alfa-mediated cytotoxicity on murine L929 tumor cells."
2.	Brain Hypoxia-Ischemia (Hypoxia Ischemia, Brain) 06/01/2001 - "To test the hypothesis that PAF mediates CNS injury in part by modulating gene transcription, we evaluated the neuroprotective efficacy of the drug BN 50730, an antagonist of the intracellular (microsomal) CNS PAF binding site, in the neonatal rat model of unilateral cerebral hypoxia-ischemia. "
3.	Inflammation (Inflammations) 05/01/1999 - "In BN 50730 treated mice (3 mg/kg) we also observed a significant reduction of the inflammation score (0.1 +/- 0.1 vs 2.5 +/- 0.2 in the untreated) and deposition of fibronectin. "
4.	Rheumatoid Arthritis 08/01/1998 - "To evaluate the efficacy and tolerance of a platelet activating factor-acether (PAF) antagonist, BN 50730, in patients with rheumatoid arthritis (RA). " 09/01/1995 - "To determine the efficacy and safety of a platelet activating factor (PAF) antagonist, BN 50730, in patients with rheumatoid arthritis. " 09/01/1995 - "Treatment of rheumatoid arthritis with platelet activating factor antagonist BN 50730."
5.	Arthritis (Polyarthritis) 05/01/1999 - "The beneficial effects in this model of joint injury after administration of the PAF antagonist BN 50730 suggest that PAF could be implicated in the pathogenesis of chronic arthritis." 02/01/1995 - "BN 50730 was able partially to prevent the development of arthritis, and was also active on established arthritis. " 05/01/1999 - "Mice with collagen induced arthritis were treated with BN 50730 (0.3, 1, 3 mg/kg) or vehicle (0.1% Tween-20 in saline) once a day, from 3 days before the induction of the arthritis to 70 days after. " 02/01/1995 - "Treatment of carrageenan induced arthritis by the platelet activating factor antagonist BN 50730."

Related Drugs and Biologics

1.	Fibronectins (Fibronectin)
2.	Platelet Activating Factor
3.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
4.	Polysorbates (PSML)
5.	Physostigmine
6.	Leukotriene B4
7.	Carrageenan
8.	Bradykinin
9.	Acetylcholine (Acetylcholine Chloride)
10.	ginkgolide B

Related Therapies and Procedures

1.	Therapeutics
2.	Ligation